CTRI/2014/09/004943已完成未知
Effect of zoledronic acid therapy on aromatase inhibitor induced bone loss in postmenopausal Hormone Responsive Early Breast Cancer
Dr Ved Prakash0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •postmenopausal hormone receptor positive early breast cancer (stage I-IIIA) patients, who had had primary surgery, did not have recurrent or metastatic disease and treated with aromatase inhibitor
排除标准
- •Premenopausal
- •Advanced disease
研究者
相似试验
已完成
2 期
Additive effect of zoledronic acid on hormone-sensitive prostate cancer patients with bone metastasis treated by hormonal therapy: a prospective, multicenter studyProstate cancerJPRN-UMIN000010765Department of Urology, Saitama Medical Center, Saitama Medical University100
已完成
Unknown
A new study to minimise the side effects of rapid maxillary expansioSide effects of rapid maxillary expansion (RME) on dental and buccal alveolar bone changesOral HealthISRCTN16744226Damascus University32
已完成
4 期
Zoledronate and fracture prevention in early postmenopausal womeMusculoskeletal - OsteoporosisOsteoporosisACTRN12612000270819Dr Mark Bolland1,054
已完成
不适用
Zoledronic acid injection prevents bone loss in spinal cord injury patientsCTRI/2018/03/012408Dr Satyaranjan Sethi60
已完成
2 期
Evaluation of Zolendronic acid in the management of high grade osteosarcomaCTRI/2011/091/000189Tata Memorial Hospital60